Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review

被引:44
作者
Volkart, Priscylla Andrade [1 ,2 ]
Bitencourt-Ferreira, Gabriela [2 ]
Souto, Andre Arigony [1 ,2 ]
de Azevedo, Walter Filgueira, Jr. [1 ,2 ]
机构
[1] Pontifical Catholic Univ Rio Grande Sul PUCRS, Grad Program Cellular & Mol Biol, Av Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil
[2] Pontifical Catholic Univ Rio Grande Sul PUCRS, Sch Sci, Av Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil
关键词
CDK2; cyclin; cellular senescence; protein-ligand interactions; drug design; cancer; DNA-DAMAGE; HUMAN CDK2; BINDING AFFINITIES; CRYSTAL-STRUCTURES; SELECTIVE CLASS; PROTEIN; INHIBITORS; LIGAND; MYC; POTENT;
D O I
10.2174/1389450120666181204165344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Cyclin-dependent kinase 2 (CDK2) has been studied due to its role in the cell-cycle progression. The elucidation of the CDK2 structure paved the way to investigate the molecular basis for inhibition of this enzyme, with the coordinated efforts combining crystallography with functional studies. Objective: Our goal here is to review recent functional and structural studies directed to understanding the role of CDK2 in cancer and senescence. Methods: There are over four hundreds of crystallographic structures available for CDK2, many of them with binding affinity information. We use this abundance of data to analyze the essential features responsible for the inhibition of CDK2 and its function in cancer and senescence. Results: The structural and affinity data available CDK2 makes it possible to have a clear view of the vital CDK2 residues involved in molecular recognition. A detailed description of the structural basis for ligand binding is of pivotal importance in the design of CDK2 inhibitors. Our analysis shows the relevance of the residues Leu 83 and Asp 86 for binding affinity. The recent findings revealing the participation of CDK2 inhibition in senescence open the possibility to explore the richness of structural and affinity data for a new era in the development of CDK2 inhibitors, targeting cellular senescence. Conclusion: Here, we analyzed structural information for CDK2 in combination with inhibitors and mapped the molecular aspects behind the strongest CDK2 inhibitors for which structures and ligand-binding affinity data were available. From this analysis, we identified the significant intermolecular interactions responsible for binding affinity. This knowledge may guide the future development of CDK2 inhibitors targeting cancer and cellular senescence.
引用
收藏
页码:716 / 726
页数:11
相关论文
共 94 条
[1]   Recent improvements to Binding MOAD: a resource for protein-ligand binding affinities and structures [J].
Ahmed, Aqeel ;
Smith, Richard D. ;
Clark, Jordan J. ;
Dunbar, James B., Jr. ;
Carlson, Heather A. .
NUCLEIC ACIDS RESEARCH, 2015, 43 (D1) :D465-D469
[2]   Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for DiabetesMellitus [J].
Ahmed, Danish ;
Sharma, Andmanju .
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2011, 2011
[3]   Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency [J].
Anderson, David R. ;
Meyers, Marvin J. ;
Kurumbail, Ravi G. ;
Caspers, Nicole ;
Poda, Gennadiy I. ;
Long, Scott A. ;
Pierce, Betsy S. ;
Mahoney, Matthew W. ;
Mourey, Robert J. ;
Parikh, Mihir D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) :4882-4884
[4]   Imidazo[1,2-a]pyridines:: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation [J].
Anderson, M ;
Beattie, JF ;
Breault, GA ;
Breed, J ;
Byth, KF ;
Culshaw, JD ;
Ellston, RPA ;
Green, S ;
Minshull, CA ;
Norman, RA ;
Pauptit, RA ;
Stanway, J ;
Thomas, AP ;
Jewsbury, PJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :3021-3026
[5]   Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors [J].
Anderson, Malcolm ;
Andrews, David M. ;
Barker, Andy J. ;
Brassington, Claire A. ;
Breed, Jason ;
Byth, Kate F. ;
Culshaw, Janet D. ;
Finlay, M. Raymond V. ;
Fisher, Eric ;
McMiken, Helen H. J. ;
Green, Clive P. ;
Heaton, Dave W. ;
Nash, Ian A. ;
Newcombe, Nicholas J. ;
Oakes, Sandra E. ;
Pauptit, Richard A. ;
Roberts, Andrew ;
Stanway, Judith J. ;
Thomas, Andrew P. ;
Tucker, Julie A. ;
Walker, Mike ;
Weir, Hazel M. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) :5487-5492
[6]   Pyridines, pyridazines and guanines as CDK2 inhibitors: a review [J].
Babu, P. Ajay ;
Narasu, M. Laxmi ;
Srinivas, K. .
ARKIVOC, 2007, :247-265
[7]   Checking on DNA damage in S phase [J].
Bartek, J ;
Lukas, C ;
Lukas, J .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (10) :792-804
[8]   Reversal of human cellular senescence:: roles of the p53 and p16 pathways [J].
Beauséjour, CM ;
Krtolica, A ;
Galimi, F ;
Narita, M ;
Lowe, SW ;
Yaswen, P ;
Campisi, J .
EMBO JOURNAL, 2003, 22 (16) :4212-4222
[9]   Binding MOAD, a high-quality protein-ligand database [J].
Benson, Mark L. ;
Smith, Richard D. ;
Khazanov, Nickolay A. ;
Dimcheff, Brandon ;
Beaver, John ;
Dresslar, Peter ;
Nerothin, Jason ;
Carlson, Heather A. .
NUCLEIC ACIDS RESEARCH, 2008, 36 :D674-D678
[10]   The Protein Data Bank [J].
Berman, HM ;
Battistuz, T ;
Bhat, TN ;
Bluhm, WF ;
Bourne, PE ;
Burkhardt, K ;
Iype, L ;
Jain, S ;
Fagan, P ;
Marvin, J ;
Padilla, D ;
Ravichandran, V ;
Schneider, B ;
Thanki, N ;
Weissig, H ;
Westbrook, JD ;
Zardecki, C .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :899-907